Trial Design & Efficacy | REVLIMID® (lenalidomide) + dexamethasone
Clinical trials with single-agent lenalidomide (25 mg, days 1-21)... | Download Table
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials | Haematologica
Visual abstract: Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial
Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma - ScienceDirect
Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma | NEJM
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial - The Lancet Oncology
REVLIMID® (lenalidomide) Plus rituximab Safety Profile
Lenalidomide - Wikipedia
Lymphoma Hub on Twitter: "CONGRESS | #ASCO20 | RE-MIND study | Tafasitamab + lenalidomide (L-MIND study) vs. lena in real-world for TNE patients with R/R #DLBCL. @GregNowakowski, from @MayoClinic, advocates for the
%20DD.jpg "Revlimid (Lenalidomide) for the Treatment of Mantle Cell Lymphoma (MCL) - Clinical Trials Arena")
Revlimid (Lenalidomide) for the Treatment of Mantle Cell Lymphoma (MCL) - Clinical Trials Arena
The University of Texas Southwestern Medical Center Myeloma Trials
Rd Continuous vs Fixed Cycle Efficacy | REVLIMID® (lenalidomide)
Maintenance Therapy Trial Design & Efficacy | REVLIMID® (lenalidomide)
Phase III Intervention Study for Multiple Myeloma
Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma - ScienceDirect
Summary of relevant clinical trials for lenalidomide in del(5q)... | Download Table
lenalidomide for Lymphoma Clinical Trial | Power
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma - Biology of Blood and Marrow Transplantation
Clinical trials with the combination of lenalidomide and rituximab... | Download Table
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
